psalexa
logo

Immunotherapy Drugs Market

Global Immunotherapy Drugs Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS11095
Available Format:

Chapter 1. Research Background

1.1. Research Objectives

1.2. Market Definition

1.3. Research Scope

1.3.1. Market Segmentation by Therapy Area

1.3.2. Market Segmentation by Types of Drug

1.3.3. Market Segmentation by End User

1.3.4. Market Segmentation by Geography

1.3.5. Analysis Period

1.3.6. Market Data Reporting Unit

1.3.6.1. Value

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By region

2.2.1.2. By industry participants

2.2.1.3. By company type

2.3. Market Size Estimation

2.4. Market Breakdown and Data Triangulation

2.5. Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1. Market Segmentation

4.1.1. Overview by Therapy Area

4.1.1.1. Cancer

4.1.1.1.1. Solid tumor

4.1.1.1.2. Malignant

4.1.1.2. Autoimmune & inflammatory diseases

4.1.1.3. Infectious diseases

4.1.1.4. Others

4.1.2. Overview by Types of Drug

4.1.2.1. Monoclonal antibodies

4.1.2.2. Adult vaccines

4.1.2.2.1. Preventive vaccines

4.1.2.2.2. Therapeutic vaccines

4.1.2.3. Checkpoint inhibitors

4.1.2.4. Interferons alpha & beta

4.1.2.5. Interleukins

4.1.2.6. Others

4.1.3. Overview by End User

4.1.3.1. Hospitals

4.1.3.2. Clinics

4.1.3.3. Others

4.2. Market Dynamics

4.2.1. Trends

4.2.2. Drivers

4.2.2.1. Impact analysis of drivers on market forecast

4.2.3. Restraints

4.2.3.1. Impact analysis of restraints on market forecast

4.2.4. Opportunities

4.3. Porter’s Five Forces Analysis

Chapter 5. Market Size and Forecast by Therapy Area

5.1. Cancer

5.1.1. Cancer, by Type

5.1.1.1. Solid tumor

5.1.1.2. Malignant

5.2. Autoimmune & Inflammatory Diseases

5.3. Infectious Diseases

Chapter 6. Market Size and Forecast by Types of Drugs

6.1. Monoclonal Antibodies

6.2. Adult Vaccines

6.2.1. Adult Vaccines, by Type

6.2.1.1. Preventive vaccines

6.2.1.2. Therapeutic vaccines

6.3. Checkpoint Inhibitors

6.4. Interferons Alpha & Beta

6.5. Interleukins

Chapter 7. Market Size and Forecast by End Users

7.1. Hospitals

7.2. Clinics

7.3. Others

Chapter 8. Market Size and Forecast by Geography

8.1. North America Immunotherapy Drugs Market

8.1.1. By Therapy Area

8.1.2. By Types of Drug

8.1.3. By End User

8.1.4. By Country – The U.S. and Canada

8.2. Europe Immunotherapy Drugs Market

8.2.1. By Therapy Area

8.2.2. By Types of Drug

8.2.3. By End User

8.2.4. By Country – Germany, the U.K., France, Italy, Spain and Rest of Europe

8.3. Asia-Pacific Immunotherapy Drugs Market

8.3.1. By Therapy Area

8.3.2. By Types of Drug

8.3.3. By End User

8.3.4. By Country –China, India, Japan, and Rest of Asia-Pacific

8.4. Latin America Immunotherapy Drugs Market

8.4.1. By Therapy Area

8.4.2. By Types of Drug

8.4.3. By End User

8.4.4. By Country – Brazil, Mexico and Rest of Latin America

8.5. Middle East & Africa (MEA) Immunotherapy Drugs Market

8.5.1. By Therapy Area

8.5.2. By Types of Drug

8.5.3. By End User

Chapter 9. Competitive Landscape

9.1. Competitive Benchmarking of Key Players

9.2. Global Strategic Developments

Chapter 10. Company Profiles

10.1. AstraZeneca plc

10.1.1. Business Overview

10.1.2. Product and Service Offerings

10.1.3. Key Financial Summary

10.1.4. Strategic Growth Plan

10.2. Eli Lilly and Company

10.2.1. Business Overview

10.2.2. Product and Service Offerings

10.2.3. Key Financial Summary

10.2.4. Strategic Growth Plan

10.3. Bristol-Myers Squibb

10.3.1. Business Overview

10.3.2. Product and Service Offerings

10.3.3. Key Financial Summary

10.3.4. Strategic Growth Plan

10.4. Johnson & Johnson

10.4.1. Business Overview

10.4.2. Product and Service Offerings

10.4.3. Key Financial Summary

10.4.4. Strategic Growth Plan

10.5. Amgen, Inc.

10.5.1. Business Overview

10.5.2. Product and Service Offerings

10.5.3. Key Financial Summary

10.5.4. Strategic Growth Plan

10.6. GlaxoSmithKline

10.6.1. Business Overview

10.6.2. Product and Service Offerings

10.6.3. Key Financial Summary

10.6.4. Strategic Growth Plan

10.7. F. Hoffmann-La Roche AG

10.7.1. Business Overview

10.7.2. Product and Service Offerings

10.7.3. Key Financial Summary

10.7.4. Strategic Growth Plan

10.8. AbbVie, Inc.

10.8.1. Business Overview

10.8.2. Product and Service Offerings

10.8.3. Key Financial Summary

10.8.4. Strategic Growth Plan

10.9. Merck & Co., Inc.

10.9.1. Business Overview

10.9.2. Product and Service Offerings

10.9.3. Key Financial Summary

10.9.4. Strategic Growth Plan

10.10. Novartis International AG

10.10.1. Business Overview

10.10.2. Product and Service Offerings

10.10.3. Key Financial Summary

10.10.4. Strategic Growth Plan

*Note: Key financial summary and strategic growth plan will be provided on best effort basis and is subject to availability during primary and secondary research.

Chapter 11. Appendix

11.1. Abbreviations

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry